ID   HROC18
AC   CVCL_0B45
SY   HROC 18
DR   CLS; 300808
DR   Cosmic; 2151360
DR   Cosmic; 2324288
DR   GEO; GSM1448095
DR   Wikidata; Q54895248
RX   PubMed=24647592;
RX   PubMed=25309914;
RX   PubMed=25574089;
RX   PubMed=25926053;
RX   PubMed=31601052;
CC   From: Linnebacher M.; University of Rostock; Rostock; Germany.
CC   Population: Caucasian.
CC   Doubling time: 35 +- 7.2 hours (PubMed=25574089).
CC   HLA typing: A*01:01:01,02:01:01; B*08:01:01,15:24:01; C*07:01:01; DPB1*01:01,04:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,13:03:01 (CLS=300808).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Cecum; UBERON=UBERON_0001153.
ST   Source(s): CLS=300808; Direct_author_submission; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 12,13
ST   D21S11: 30,33.2
ST   D5S818: 9,11
ST   D7S820: 8,11
ST   TH01: 7,8
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C0UD ! B-LCL-HROC18
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 02-05-24; Version: 18
//
RX   PubMed=24647592; DOI=10.3892/or.2014.3097;
RA   Huhns M., Salem T., Schneider B., Krohn M., Linnebacher M., Prall F.;
RT   "PTEN mutation, loss of heterozygosity, promoter methylation and
RT   expression in colorectal carcinoma: two hits on the gene?";
RL   Oncol. Rep. 31:2236-2244(2014).
//
RX   PubMed=25309914; DOI=10.1155/2014/568693;
RA   Lange F., Franz B., Maletzki C., Linnebacher M., Huhns M., Jaster R.;
RT   "Biological and molecular effects of small molecule kinase inhibitors
RT   on low-passage human colorectal cancer cell lines.";
RL   BioMed Res. Int. 2014:568693.1-568693.13(2014).
//
RX   PubMed=25574089; DOI=10.3748/wjg.v21.i1.164;
RA   Maletzki C., Gock M., Randow M., Klar E., Huhns M., Prall F.,
RA   Linnebacher M.;
RT   "Establishment and characterization of cell lines from chromosomal
RT   instable colorectal cancer.";
RL   World J. Gastroenterol. 21:164-176(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=31601052; DOI=10.3390/cancers11101520;
RA   Mullins C.S., Micheel B., Matschos S., Leuchter M., Burtin F.,
RA   Krohn M., Huhns M., Klar E., Prall F., Linnebacher M.;
RT   "Integrated biobanking and tumor model establishment of human
RT   colorectal carcinoma provides excellent tools for preclinical
RT   research.";
RL   Cancers (Basel) 11:1520.1-1520.18(2019).
//